KIR2DL2/DL3+NKs and Helios+Tregs in peripheral blood predict nivolumab response in patients with metastatic renal cell cancer.
Sara SantagataAnna Maria TrottaCrescenzo D'AlterioMaria NapolitanoGiuseppina ReaMarilena Di NapoliLuigi PortellaCaterina IeranòGiuseppe GuardascioneElisabetta CoppolaChristophe CauxBertrand DuboisHelen J BoyleJoan CarlesSabrina RossettiRosa AzzaroFlorinda FeroceSisto PerdonàMario FordelloneAnna Maria BelloDaniela CalifanoPaolo ChiodiniSandro PignataStefania ScalaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Pre-treatment evaluation of Helios+Tregs/KIR2DL2/DL3+NKs and one-month post-treatment CD3+/ KIR2DL2/DL3+NKs will predict nivolumab response in mRCCs.